SEC 13F Intelligence

Managers / Q2 2025 · view latest →

Privium Fund Management B.V.

CIK 0001795097 · GUSTAV MAHLERPLEIN 3, AMSTERDAM, P7, 1082 MS · 31 20 462 6644

Reported Value
$464M
Q2 2025
Positions
55
Filings on Record
20
2019–present window
Filed
Jul 30, 2025
original filing

Summary

Privium Fund Management B.V. reported $464M in U.S.-listed holdings across 55 positions for Q2 2025.

Its largest position, SPOT, represents 18.3% of the portfolio.

Compared with Q1 2025, the fund opened 7 new positions and exited 8.

Portfolio Metrics

Turnover
+6.8%
vs prior filed quarter
Top-10 Concentration
+81.5%
share of reported value
Largest Position
+18.3%
Spotify Technology S A
New / Exited
7 / 8
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’21: $504MQ4 ’21Q1 ’22: $452MQ2 ’22: $302MQ3 ’22: $275MQ3 ’22Q4 ’22: $264MQ1 ’23: $298MQ2 ’23: $347MQ2 ’23Q3 ’23: $336MQ4 ’23: $359MQ1 ’24: $374MQ1 ’24Q2 ’24: $392MQ3 ’24: $402MQ4 ’24: $442MQ4 ’24Q1 ’25: $384MQ2 ’25: $464MQ3 ’25: $556MQ3 ’25Q4 ’25: $543MQ1 ’26: $480Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 88.6%ADR: 8.9%Other: 2.4%ETP: 0.2%
  • Common Stock · 88.6% · $410M
  • ADR · 8.9% · $41M
  • Other · 2.4% · $11M
  • ETP · 0.2% · $761,159

Quarter-over-Quarter Changes full breakdown →

vs Q1 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
COINCOINBASE GLOBAL INCNEW+70.0K70.0K+$24M$24M
BIIBBIOGEN INCNEW+20.5K20.5K+$3M$3M
CVNACARVANA CONEW+5.0K5.0K+$2M$2M
BNTXBIONTECH SENEW+11.0K11.0K+$1M$1M
HIMSHIMS & HERS HEALTH INCNEW+22.0K22.0K+$1M$1M
SRPTSAREPTA THERAPEUTICS INCNEW+39.4K39.4K+$697,774$697,774
TDWTIDEWATER INC NEWNEW+5.3K5.3K+$255,195$255,195
SNOWSNOWFLAKE INCSOLD OUT−48.0K0−$7M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2025

55 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SPOTSPOTIFY TECHNOLOGY S Ahistory →SHS18.30%$85M114.0K
2TSLATESLA INChistory →COM16.11%$75M242.0K
3SHOPSHOPIFY INChistory →CL A SUB VTG SHS10.57%$49M430.0K
4PLTRPALANTIR TECHNOLOGIES INChistory →CL A10.05%$47M350.0K
5AMZNAMAZON COM INChistory →COM7.07%$33M149.0K
6SESEA LTDhistory →SPONSORD ADS7.01%$33M210.0K
7COINCOINBASE GLOBAL INChistory →COM CL A5.22%$24M70.0K
8NVDANVIDIA CORPORATIONhistory →COM2.70%$13M81.0K
9IONSIONIS PHARMACEUTICALS INChistory →COM2.31%$11M267.6K
10PROQR THRAPEUTICS N VSHS EURO2.17%$10M5.00M
11ARWRARROWHEAD PHARMACEUTICALS INhistory →COM2.13%$10M612.2K
12RAREULTRAGENYX PHARMACEUTICAL INhistory →COM1.98%$9M253.3K
13QUREUNIQURE NVhistory →SHS1.35%$6M447.5K
14AXSMAXSOME THERAPEUTICS INChistory →COM1.17%$5M52.7K
15MRKMERCK & CO INChistory →COM1.04%$5M59.1K
16ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM1.02%$5M344.5K
17ZLABZAI LAB LTDhistory →ADR1.00%$5M132.2K
18VRTXVERTEX PHARMACEUTICALS INCCOM0.81%$4M8.3K
19ACADACADIA PHARMACEUTICALS INCCOM0.68%$3M148.4K
20MRNAMODERNA INCCOM0.64%$3M103.4K
21BIIBBIOGEN INCCOM0.58%$3M20.5K
22CRSPCRISPR THERAPEUTICS AGNAMEN AKT0.47%$2M44.7K
23ABEVAMBEV SASPONSORED ADR0.42%$2M795.8K
24CVNACARVANA COCL A0.36%$2M5.0K
25URGNUROGEN PHARMA LTDCOM0.30%$1M107.6K
26ROIVROIVANT SCIENCES LTDSHS0.30%$1M126.9K
27AVIDITY BIOSCIENCES INCCOM0.28%$1M46.0K
28KRYSKRYSTAL BIOTECH INCCOM0.28%$1M9.3K
29BNTXBIONTECH SESPONSORED ADS0.25%$1M11.0K
30RCKTROCKET PHARMACEUTICALS INCCOM0.24%$1M432.8K
31HIMSHIMS & HERS HEALTH INCCOM CL A0.24%$1M22.0K
32MEIRAGTX HLDGS PLCCOM0.23%$1M163.0K
33PFEPFIZER INCCOM0.20%$927,20637.0K
34WVEWAVE LIFE SCIENCES LTDSHS0.19%$883,786135.6K
35PAASPAN AMERN SILVER CORPCOM0.18%$844,81529.7K
36NOVNOV INCCOM0.18%$825,27863.9K
37FDMT4D MOLECULAR THERAPEUTICS INCOM0.18%$819,451197.5K
38URNMSPROTT FDS TRURANIUM MINERS E0.16%$761,15916.3K
39LXEOLEXEO THERAPEUTICS INCCOM0.16%$752,662178.4K
40VZLAVIZSLA SILVER CORPCOM NEW0.16%$732,307250.8K
41SRPTSAREPTA THERAPEUTICS INCCOM0.15%$697,77439.4K
42AUTLAUTOLUS THERAPEUTICS PLCSPON ADS0.15%$673,585294.1K
43SASEABRIDGE GOLD INCCOM0.14%$648,32944.1K
44RXRXRECURSION PHARMACEUTICALS INCL A0.13%$610,470119.0K
45VALVALARIS LTDCL A0.13%$605,95213.8K
46EMXEMX RTY CORPCOM0.12%$544,590217.0K
47SDSANDRIDGE ENERGY INCCOM NEW0.09%$400,94837.0K
48NENOBLE CORP PLCORD SHS A0.08%$392,03514.3K
49TSHATAYSHA GENE THERAPIES INCCOM SHS0.07%$315,666134.9K
50TDWTIDEWATER INC NEWCOM0.06%$255,1955.3K
51SBSWSIBANYE STILLWATER LTDSPONSORED ADR0.05%$247,81134.0K
52DYNDYNE THERAPEUTICS INCCOM0.05%$239,27327.6K
53ALXOALX ONCOLOGY HLDGS INCCOM0.05%$220,575509.1K
54FATEFATE THERAPEUTICS INCCOM0.03%$126,643111.1K
55VYGRVOYAGER THERAPEUTICS INCCOM0.02%$78,75225.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$480M60May 5, 202613F-HRchanges · EDGAR ↗
Q4 2025$543M57Feb 3, 202613F-HRchanges · EDGAR ↗
Q3 2025$556M59Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$464M55Jul 30, 202513F-HRchanges · EDGAR ↗
Q1 2025$384M56May 9, 202513F-HRchanges · EDGAR ↗
Q4 2024$442M64Feb 11, 202513F-HRchanges · EDGAR ↗
Q3 2024$402M82Nov 1, 202413F-HRchanges · EDGAR ↗
Q2 2024$392M129Aug 1, 202413F-HRchanges · EDGAR ↗
Q1 2024$374M117Apr 30, 202413F-HRchanges · EDGAR ↗
Q4 2023$359M114Feb 26, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$336M115Nov 6, 202313F-HRchanges · EDGAR ↗
Q2 2023$347M124Jul 26, 2023RESTATEMENTchanges · EDGAR ↗
Q1 2023$298M126May 3, 202313F-HRchanges · EDGAR ↗
Q4 2022$264M150Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$275M226Nov 3, 202213F-HRchanges · EDGAR ↗
Q2 2022$302M252Jul 28, 202213F-HRchanges · EDGAR ↗
Q1 2022$452M279May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$504M253Feb 9, 202213F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.